Core Concepts
Targeted therapies offer hope for improved survival in advanced biliary tract cancers.
Stats
Over the past decade, the utilization of next-generation sequencing has led to the identification of multiple actionable somatic aberrations in BTCs.
415 trials were identified in a literature search for targeted therapies in patients with advanced BTCs.
Approximately 68% of patients with BTCs have an actionable mutation.
Quotes
"Targeted agents can improve survival in patients with advanced BTCs."
"The therapeutic landscape of targeted therapies for patients with advanced BTCs continues to evolve based on improvements in detection of genomic alterations."